ライフサイエンスコーパス: replacement therapy

1 tem, or death), and interventions (ie, renal replacement therapy).

2 aseline value or a new requirement for renal replacement therapy).

3 sex steroid production that require hormone replacement therapy.

4 le to discontinue intravenous immunoglobulin replacement therapy.

5 , physical activity, medication, and hormone-replacement therapy.

6 for drug discovery, and eventually for cell replacement therapy.

7 was treated with repeated sessions of renal replacement therapy.

8 effectively treated with the use of hormone replacement therapy.

9 prospective randomized trials using hormonal replacement therapy.

10 d chimerism and are free from immunoglobulin replacement therapy.

11 ther an early or a delayed strategy of renal-replacement therapy.

12 delayed-strategy group did not receive renal-replacement therapy.

13 es and behaviour was stronger under dopamine replacement therapy.

14 tervention, and the use of pancreatic enzyme-replacement therapy.

15 unlimited source of human cells for pancreas replacement therapy.

16 can theoretically also be treated with gene replacement therapy.

17 delayed strategy for the initiation of renal-replacement therapy.

18 ic cell types for disease modelling and cell replacement therapy.

19 age kidney disease (ESKD) and need for renal replacement therapy.

20 lia A may depend on the concentrate used for replacement therapy.

21 tation may represent a permanent parathyroid replacement therapy.

22 lop end-stage renal disease, requiring renal replacement therapy.

23 on hours of 130 and one third required renal replacement therapy.

24 growth hormone deficiency and was started on replacement therapy.

25 mine for cocaine addiction go beyond that of replacement therapy.

26 cy, or with any contraindications to hormone-replacement therapy.

27 o human female infertility and mitochondrial replacement therapy.

28 neurons, supporting the feasibility of gene replacement therapy.

29 rate of acute kidney injury and use of renal replacement therapy.

30 uch as cell/organ transplant or gene/protein replacement therapy.

31 steoporosis, systemic steroids, or oestrogen-replacement therapy.

32 osite outcome of hospital mortality or renal replacement therapy.

33 renal function and discontinuation of renal replacement therapy.

34 vitro disease modeling and personalized cell replacement therapy.

35 and end stage kidney disease requiring renal replacement therapy.

36 influences circuit life in continuous renal replacement therapy.

37 e was >1.2mg/dL or they were receiving renal replacement therapy.

38 ntricular mechanical assist device, or renal replacement therapy.

39 an 10 mL/min/1.73 m2, or initiation of renal replacement therapy.

40 ased use of mechanical ventilation and renal-replacement therapy.

41 rate anticoagulation during continuous renal replacement therapy.

42 nce, however, was attenuated by use of renal replacement therapy.

43 een SP risk and physical activity or hormone replacement therapy.

44 of 250 or 150 mL/min during continuous renal replacement therapy.

45 ia, which is currently managed by preemptive replacement therapy.

46 uture studies related to intervertebral disc replacement therapy.

47 ically ill adults requiring continuous renal replacement therapy.

48 Continuous renal replacement therapy.

49 generation of cell pools for autologous cell replacement therapies.

50 des a foundation for the development of cell replacement therapies.

51 r, and improved the success of photoreceptor replacement therapies.

52 ls are potential sources for cell and tissue replacement therapies.

53 insufficiency are limited to corticosteroid replacement therapies.

54 tion slowed the clinical development of cell replacement therapies.

55 ay use hemodialysis (1D) or continuous renal replacement therapy (1D).

56 ntilation; 5 (19%) received continuous renal-replacement therapy; 22 (81%) received empirical antibio

57 f the children managed with continuous renal replacement therapy, 26 (58%) survived: 19 were successf

58 cked cessation medications, 96% had nicotine replacement therapy, 28% had bupropion, and 1% had varen

59 nt therapy compared with those without renal replacement therapy (47.3% vs 71.8%; p < 0.001) overall.

60 pport (79.4% vs 55.0%; p < 0.001), and renal replacement therapy (48.8% vs 22.1%; p < 0.001).

61 sopressors (23.2% vs 10.9%; P < .001), renal replacement therapy (49.6% vs 30.3%; P < .001), and prio

62 er for those receiving intubation (42.5%) or replacement therapy (51.9%).

63 cal support (27% vs 0%, P < 0.01), and renal replacement therapy (61% vs 26%, P < 0.01).

64 mote ischemic preconditioning received renal replacement therapy (7 [5.8%] vs 19 [15.8%]; absolute ri

65 e (a) the extent to which age at first renal replacement therapy, achievement of developmental milest

66 ease make it easier to detect the effects of replacement therapy against the background of severe vis

67 disorder, treatable with recombinant enzyme replacement therapy (agalsidase).

68 man pluripotent stem cells for photoreceptor replacement therapies aimed at photoreceptor regeneratio

69 Current prophylactic replacement therapy, although effective, is difficult to

70 iPSCMNs as a source of motoneurons for cell replacement therapies and to study motoneuron diseases s

71 neurons (iPSCMNs) are sought for use in cell replacement therapies and treatment strategies for moton

72 of harm reduction options, such as nicotine replacement therapy and electronic cigarettes (e-cigaret

73 hospital discharge, examined rates of renal replacement therapy and fluid overload, and measured bio

74 clarify the association between testosterone-replacement therapy and major adverse cardiovascular out

75 otential for intracerebrospinal fluid enzyme replacement therapy and should be further explored as a

76 ations may be good candidates for riboflavin replacement therapy and suggests that either the mutatio

77 tality), overall and with respect to hormone replacement therapy and tamoxifen treatment.

78 uit date, all participants received nicotine replacement therapy and their smoking behavior was obser

79 ce and by pharmacotherapies such as nicotine replacement therapy and varenicline tartrate may aid ces

80 ge, systemic congestion, respiratory support/replacement therapies, and other issues relevant to the

81 0% required vasopressors, 17% required renal replacement therapy, and 28% had liver impairment (bilir

82 ormative strategies for vaccination, protein replacement therapy, and genome editing, collectively af

83 eater need for mechanical ventilation, renal replacement therapy, and ICU stay in patients in the hig

84 nic Health Evaluation II score, use of renal replacement therapy, and infection by nonfermenting gram

85 acute kidney injury, even with ongoing renal replacement therapy, and is sufficient to cause acute ki

86 Only 10 (11%) could provide renal replacement therapy, and only 18 (20%) provided any form

87 , type 2 diabetes and parity, use of hormone replacement therapy, and oral contraceptives in women.

88 usted for nodal status, prior use of hormone replacement therapy, and prior chemotherapy (HR, 0.80; 9

89 ations for strategies to be used for protein replacement therapy, and they also suggest that the base

90 dosage and timing of antihormone or hormone replacement therapies as part of a personalized medicine

91 utility (RAF-patient death or need for renal replacement therapy at 3 months) after simultaneous live

92 s inserted preoperatively, or need for renal replacement therapy at any time postoperatively.

93 Together, our findings suggest that hormone replacement therapy benefits cognitive aging, in part by

94 bility, sales, and affordability of nicotine replacement therapy, bupropion, and varenicline in the S

95 exocrine pancreatic insufficiency requiring replacement therapy but none of the affected individuals

96 antation is now an established form of renal replacement therapy, but the efficacy and safety of the

97 logical conditions most appropriate for cell replacement therapy by considering its potential efficac

98 Although factor VIII (FVIII) replacement therapy can be lifesaving for patients with

99 Continuous renal replacement therapy can be used successfully in critical

100 Given that immunoglobulin replacement therapy can effectively prevent the recurren

101 on's disease (PD) causes hypokinesia, but DA replacement therapy can elicit exaggerated voluntary and

102 ad potential in applications such as protein replacement therapy, cancer immunotherapy, and genomic e

103 tensin II receptor blockers, lactates, renal replacement therapy, chronic heart disease, and indicati

104 um anticoagulation prolongs continuous renal replacement therapy circuit life compared with regional

105 nificantly lower in patients requiring renal replacement therapy compared with those without renal re

106 Our results suggest that growth hormone replacement therapy could be protective against fracture

107 Continuous renal replacement therapy (CRRT) benefits patients with renal

108 AKI duration (P = 0.59) and rates of renal replacement therapy did not differ between study arms (6

109 ver sufficient renal function allowing renal replacement therapy discontinuation when baseline estima

110 However, standard renal replacement therapy does not correct this defect in pati

111 and increased each year in those on dopamine replacement therapy (DRT) and decreased in those not on

112 (ICD) are commonly associated with dopamine replacement therapy (DRT) in patients with Parkinson's d

113 Secondary end points included use of renal replacement therapy, duration of intensive care unit sta

114 one patients (50.0%) were treated with renal replacement therapy during extracorporeal membrane oxyge

115 , vasoactive agent use, and receipt of renal replacement therapy during ICU stay.

116 o Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE), at 1 year, eliglustat was

117 treated and 33 Fabry males treated by enzyme replacement therapy (ERT) and 54 untreated and 19 ERT-tr

118 e-modified cells is an alternative to enzyme replacement therapy (ERT) and allogeneic HSCT that has s

119 Together, these data suggest that CBS enzyme replacement therapy (ERT) is a promising approach for th

120 Enzyme replacement therapy (ERT) partially and temporarily reli

121 ublil and colleagues demonstrate that enzyme replacement therapy (ERT) provides long-term amelioratio

122 patients, which was not corrected by enzyme replacement therapy (ERT).

123 Some current enzyme replacement therapies (ERTs) for lysosomal storage disor

124 The need for renal replacement therapy (five [3.2%] and six [3.9%] patients

125 In particular, the promise of cell replacement therapies for clinical intervention has led

126 ner ear development but also to improve cell replacement therapies for hearing disorders.

127 Cell replacement therapies for neurodegenerative disease have

128 f studies support the practice of fibrinogen replacement therapy for acquired coagulopathies, and add

129 ialysis dependency after initiation of renal replacement therapy for acute kidney injury.

130 indicate the earlier use of continuous renal replacement therapy for both renal dysfunction and detox

131 nesis inhibitors, can be repurposed for TSP1 replacement therapy for CCMs.

132 from stem cells hold great promise for cell replacement therapy for diabetes.

133 s for infertility treatment or mitochondrial replacement therapy for mtDNA disease.

134 vide a significant step forward towards cell replacement therapy for Parkinson's disease (PD).

135 beta-like cells holds great promise for cell replacement therapy for patients suffering from diabetes

136 Gene replacement therapy for RPGR-XLRP was hampered by the re

137 et transplantation is a successful beta-cell replacement therapy for selected patients with type 1 di

138 et transplantation is a successful beta-cell replacement therapy for selected patients with type 1 di

139 d delivery of enzymes to lysosomes in enzyme replacement therapy for the treatment of lysosomal stora

140 dialysis (PD) is a life-saving form of renal replacement therapy for those with end-stage kidney dise

141 g very low nicotine cigarettes plus nicotine replacement therapy) for 30 days before their target qui

142 ssociation between RBC transfusion and renal replacement therapy-free days, mechanical ventilator-fre

143 Time to initiate continuous renal replacement therapy from PICU admission was lower in sur

144 r the development of safe and effective cell-replacement therapies, given that studies in mouse model

145 omposite primary end point of death or renal-replacement therapy had occurred in 158 of the 344 patie

146 nt of the plaque, whereas a systemic miR-100 replacement therapy had protective effects and attenuate

147 While testosterone replacement therapy has been shown to improve bone miner

148 velopment of stem cell technologies for cell replacement therapy has progressed rapidly in recent yea

149 Agonist-replacement therapies have been successfully used for tr

150 Enzyme replacement therapies have revolutionized patient treatm

151 reditary mtDNA disease through mitochondrial replacement therapy have roused interest in the organell

152 n post kidney transplantation, chronic renal replacement therapy (hemodialysis or peritoneal dialysis

153 generation of functional beta-cells for cell replacement therapies; however, these attempts have only

154 HR, 1.25; 95% CI, 1.08 to 1.43), and hormone replacement therapy (HR, 1.27; 95% CI, 1.08 to 1.49) wer

155 model and to estimate the effects of hormone replacement therapy (HRT) use and smoking.

156 5% CI, 1.02 to 1.70), current use of hormone replacement therapy (HRT; OR, 1.84; 95% CI, 1.38 to 2.44

157 ng or reversing the disease, developing cell replacement therapy, improving management and care, prev

158 rom ex vivo cellular manipulations to enzyme replacement therapies in humans.

159 s critical for stringent evaluation of novel replacement therapies in type 1 diabetes.

160 be interpreted in the development of future replacement therapies in type 1 diabetes.

161 free of ventilation, vasopressors and renal replacement therapy in 28-day and 1-year survivors with

162 continuous mechanical ventilation and renal replacement therapy in a long-term care hospital who had

163 acute insulin-independent effects of leptin replacement therapy in a streptozotocin-induced rat mode

164 delayed strategy averted the need for renal-replacement therapy in an appreciable number of patients

165 We conducted a phase 3 trial of enzyme-replacement therapy in children and adults with lysosoma

166 The timing of renal-replacement therapy in critically ill patients who have

167 ugs were used in 23 patients (68%) and renal replacement therapy in eight patients (24%).

168 potential for gene delivery to BCs and gene replacement therapy in human CSNB1.

169 The main goal of dopamine cell replacement therapy in Parkinson disease (PD) is to prov

170 ebilitating side-effects of chronic dopamine replacement therapy in Parkinson's disease (PD).

171 apeutic and dyskinetic responses to dopamine replacement therapy in PD.

172 The guidelines for continuous renal replacement therapy in pediatric acute liver failure wer

173 free of ventilation, vasopressors, and renal replacement therapy in septic shock in 28-day survivors

174 tantial subgroup of patients requiring renal replacement therapy in the ICU.

175 There was less use of renal replacement therapy in the vasopressin group than in the

176 h to the first clinical visit (before enzyme replacement therapy) in 499 adult patients (mean age 43

177 Immunoglobulin replacement therapy increased S. aureus-specific IgG in

178 Dopamine replacement therapy increased the rate of acceptance for

179 red thirty adult patients who required renal replacement therapy initiation in the ICU.

180 espiratory and hemodynamic supports at renal replacement therapy initiation, similarly distributed ac

181 ment therapy (positive fluid balance x renal replacement therapy interaction (adjusted hazard ratio r

182 ients received mechanical ventilation, renal replacement therapy, invasive monitoring, vasopressor su

183 t severe complication of factor VIII (FVIII) replacement therapy involves the formation of FVIII neut

184 Gene replacement therapy is a promising strategy for treatmen

185 In Parkinson's disease, long-term dopamine replacement therapy is complicated by the appearance of

186 However, hormone replacement therapy is demonstrated to increase cancer r

187 Hormone replacement therapy is effective but is not without risk

188 Glucocorticoid replacement therapy is the mainstay of treatment for con

189 atment is liver transplantation, whereas AAT replacement therapy is therapeutic for emphysema.

190 Kidney replacement therapy is used when complications cannot be

191 Continuous renal replacement therapy is valuable for surgical patients wi

192 Despite the benefits of enzyme replacement therapy, it has limitations-most importantly

193 on recently put additional restrictions on T replacement therapy labeling and called for additional s

194 nitiate early and high-dose continuous renal replacement therapy led to increased survival with maxim

195 eferred initially (1D), but continuous renal replacement therapies may be considered if hemodialysis

196 In conclusion, before treatment with enzyme replacement therapy, men with classical Fabry disease ha

197 , Tyrer-Cuzick risk, smoking, use of hormone replacement therapy, menopausal status, baseline menopau

198 esults suggest that efficacy of C1-inhibitor replacement therapy might not be a direct function of pl

199 Renal replacement therapy modified the association between sta

200 r at enrollment (P < 0.001) and used hormone replacement therapy more often (P < 0.003).

201 Rates of renal replacement therapy, mortality, and serious adverse even

202 nomes could pose a problem for mitochondrial replacement therapy (MRT).

203 ritance of pathogenic mtDNA by mitochondrial replacement therapy (MRT).

204 as potential repercussions for mitochondrial replacement therapy (MRT; see description of currently e

205 Of patients receiving renal replacement therapy, neither positive (adjusted odds rat

206 only, former smokers with long-term nicotine replacement therapy (NRT) use only, long-term dual users

207 ta illustrate disparities in access to renal replacement therapy of any kind and in the use of transp

208 cient delivery of messenger RNAs for protein replacement therapies offers great promise but remains c

209 that the impact of the withdrawal of hormone replacement therapy on density reduction was larger than

210 Mitochondrial replacement therapies or techniques (MRT) circumventing

211 ow cardiac output syndrome but not for renal replacement therapy or deep sternal wound infection.

212 , length, site, and mode of continuous renal replacement therapy or international normalized ratio ha

213 ular disease and cancer, and without hormone replacement therapy or lipid-lowering medications at bas

214 t 40 hours apart, on treatment without renal replacement therapy or liver transplantation) or SCr at

215 as associated with a decreased risk of renal replacement therapy (OR, 0.26 [95% CI, 0.11-0.60]).

216 R, 2.38 [95% CI, 1.30-4.35]; I2 = 2%), renal replacement therapy (OR, 1.90 [95% CI, 1.25-2.90]; I2 =

217 ted for at least 1 month, the start of renal replacement therapy, or an eGFR less than 10 mL/min/1.73

218 ntaining oral contraceptives (eOC), hormonal replacement therapy, or angiotensin-converting enzyme in

219 omerular filtration rate, the need for renal-replacement therapy, or death from renal causes (hazard

220 serum creatinine level, initiation of renal-replacement therapy, or death from renal disease) and in

221 estimated glomerular filtration rate, renal replacement therapy, or renal death).

222 scuss available treatments, including enzyme replacement therapy, oral lipid-lowering therapy, stem-c

223 0001, p < 0.0001, and p = 0.0004), and renal replacement therapy (p = 0.0008, p = 0.0008, and p = 0.0

224 te (P = 0.041), and BG positivity with renal replacement therapy (P = 0.05) and study site (P = 0.01)

225 aller proportion of patients receiving renal-replacement therapy (P=0.04) and a shorter duration of h

226 ort-term composite end point of death, renal-replacement therapy, perioperative myocardial infarction

227 Oral pancreatic enzyme replacement therapy (PERT) with pancreatin produces unsa

228 Even after 4 days of renal replacement therapy, plasma from patients with septic sh

229 Renal-replacement therapy poses several practical and ethical

230 h was attenuated in those who received renal replacement therapy (positive fluid balance x renal repl

231 Estradiol-based contraceptives and hormonal replacement therapy predispose women to Candida albicans

232 ssessment of insulin resistance, and hormone replacement therapy, premature menopause was associated

233 ovarian syndrome who was undergoing hormone replacement therapy presented with a 6-month history of

234 placement therapy versus patients with renal replacement therapy prior to extracorporeal membrane oxy

235 ia and 45 of these received continuous renal replacement therapy prior to transplantation or recovery

236 ifferentiate pluripotent stem cells for cell replacement therapies promise exciting avenues for treat

237 (mechanical ventilation, vasopressors, renal replacement therapy) provided in the ICU and outcomes of

238 associated outcomes including need for renal replacement therapy, rehospitalization, and death, accor

239 mortality rate in patients requiring kidney replacement therapy remains approximately 50%.

240 umor in children, and microRNA-34a (miR-34a) replacement therapy represents a new treatment strategy.

241 re-existing ESRD and CKD not requiring renal replacement therapy, respectively.

242 Optimal timing of initiation of renal replacement therapy (RRT) for severe acute kidney injury

243 Renal failure requiring renal replacement therapy (RRT) has detrimental effects on qua

244 We evaluated the effect of renal replacement therapy (RRT) on serum ammonia level and out

245 atients with established AKI requiring renal replacement therapy (RRT) were excluded.

246 ne clearance 0-236mL/min; 29 receiving renal replacement therapy (RRT)) were subjected to population

247 ne clearance 0-236mL/min; 29 receiving renal replacement therapy (RRT)) were subjected to population

248 ssure (BP), decreased kidney function, renal replacement therapy (RRT), and death.

249 age III, and 25 patients (5%) required renal replacement therapy (RRT).

250 were renal (incident renal failure and renal replacement therapy [RRT]) and bone events (incident hip

251 extracorporeal membrane oxygenation or renal replacement therapy, severe preimplant tricuspid regurgi

252 Continuous renal replacement therapy should be considered at an early sta

253 a liver transplant, use of continuous renal replacement therapy significantly improved survival (HR,

254 y 48 hours after initiating continuous renal replacement therapy significantly improved survival (HR,

255 Surfactant replacement therapy (SRT) involves instillation of a liq

256 e the potential to enable cell-based insulin replacement therapies (such as human islet or stem cell-

257 problematic and costly complication of FVIII replacement therapy that affects up to 30% of previously

258 After ending hormonal replacement therapy, three of eight women became symptom

259 ent composite of death through day 30, renal-replacement therapy through day 30, perioperative myocar

260 ficient alternative for applications in cell-replacement therapies to treat neurodegeneration in AD.

261 lly, be due to the failure of glucocorticoid replacement therapy to closely resemble physiological di

262 m of human ASM, is being developed as enzyme replacement therapy to treat the non-neurological manife

263 association between exposure to testosterone replacement therapy (TRT) and prostate cancer risk is co

264 irst birth, breastfeeding, menarche, hormone replacement therapy use, somatotype at age 18, benign br

265 index, time since menopause, use of hormone replacement therapy, use of calcium supplements, or use

266 inical application of personalized beta-cell replacement therapies using patient-derived stem cells.

267 Continuous renal replacement therapy using blood flow rate set at 250 mL/

268 Cell replacement therapy, using Hcrt-expressing neurons gener

269 Gene replacement therapies utilizing adeno-associated viral (

270 red significantly for patients without renal replacement therapy versus patients with renal replaceme

271 be for specific lysosomal disorders (enzyme replacement therapy via intrathecal or intracerebroventr

272 king and treatment characteristics (nicotine replacement therapy vs. other pharmacotherapy; group vs.

273 The evidence about nicotine replacement therapies was inconclusive (RR: 1.22; 95% CI

274 .98; P=0.03), and the relative risk of renal-replacement therapy was 0.71 (95% CI, 0.49 to 1.03; P=0.

275 With the delayed strategy, renal-replacement therapy was initiated if at least one of the

276 Renal-replacement therapy was initiated in 13 of 4687 patients

277 ath or severe renal failure leading to renal-replacement therapy was lower among those who initially

278 Time from diagnosis of AAN to renal replacement therapy was relatively short (1 [0-15] years

279 ce but required prolonged oral delivery once replacement therapy was resumed.

280 With the early strategy, renal-replacement therapy was started immediately after random

281 an area of interest since intravenous enzyme replacement therapy was successfully introduced for the

282 um creatinine or a new requirement for renal replacement therapy was within the protocol-defined noni

283 kidney injury treated with continuous renal replacement therapy, we found no association of RBC tran

284 free of ventilation, vasopressors, and renal replacement therapy were highly significantly associated

285 on and perinatal health; effects of nicotine replacement therapy were not significant.

286 ution, and discontinuation of immunoglobulin replacement therapy were recorded.

287 elivery of a novel mouse monoclonal antibody replacement therapy, which acts as an agonist for the ec

288 s are especially attractive targets for gene replacement therapy, which appears to be clinically effe

289 vitro and in vivo and suggests that miR-34a replacement therapy, which is currently being tested in

290 ase in the United States without prior renal replacement therapy who had incident vascular access for

291 iciency receiving their usual glucocorticoid replacement therapy who were part of the CaHASE study.

292 Existing treatment relies on replacement therapy with clotting factors, either at the

293 Replacement therapy with factor VIII (FVIII) is used in

294 Cell replacement therapy with human pluripotent stem cell-der

295 The standard treatment is thyroid hormone replacement therapy with levothyroxine.

296 uated the safety and effectiveness of enzyme-replacement therapy with sebelipase alfa (administered i

297 predictive biomarker of response to nicotine replacement therapy, with increased quit rates in slower

298 ath or severe renal failure leading to renal-replacement therapy within 30 days after randomization.

299 ove first value or initiation of acute renal-replacement therapy, within the first 5 days of hospital

300 Continuous renal replacement therapy without anticoagulation was more lik